Xencor, Inc.

Duc-Hanh Thi Nguyen

John R Desjarlais

Matthew J Bernett

Gregory L Moore

Arthur J Chirino

Jonathan Zalevsky

Sergei A Ezhevsky

Darian Cash

Gregory Alan Lazar

Sher Bahadur Karki

Umesh Muchhal

John O Richards

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

Optimized antibodies that target HM1.24

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.

Method of treatment using adiponectin variants

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Adiponectin variants

A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4&#xb0; C. for one week in 10 mM PO, 150 mM NaCl buffer.

Pharmaceutical compositions of adiponectin variants and methods of storage

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Growing community of inventors

Sylmar, CA, United States of America

Duc-Hanh Thi Nguyen